DaklinzaActive Ingredient(s): Daclatasvir
FDA Approved: * July 24, 2015
Pharm Company: * BRISTOL MYERS SQUIBB
Daclatasvir, sold under the brand name Daklinza, is an antiviral medication used in combination with other medications to treat hepatitis C (HCV). The other medications used in combination include sofosbuvir, ribavirin, and interferon, vary depending on the virus type and whether the person has cirrhosis. It is taken by mouth. Common side effects when used with sofusbivir and daclatasvir include headache, feeling tired, and nausea.&... [wikipedia]* May have multiple approval dates, manufacturers, or labelers.